My-Anh Nguyen1, Denuja Karunakaran1, Michèle Geoffrion1, Henry S Cheng1, Kristofferson Tandoc1, Ljubica Perisic Matic1, Ulf Hedin1, Lars Maegdefessel1, Jason E Fish1, Katey J Rayner2. 1. From the University of Ottawa Heart Institute, Ontario, Canada (M.-A.N., D.K., M.G., K.T., K.J.R.); Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ontario, Canada (M.-A.N., K.J.R.); Toronto General Research Hospital Institute, University Health Network, Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada (H.S.C., J.E.F.); Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (L.P.M., U.H.); and Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.). 2. From the University of Ottawa Heart Institute, Ontario, Canada (M.-A.N., D.K., M.G., K.T., K.J.R.); Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ontario, Canada (M.-A.N., K.J.R.); Toronto General Research Hospital Institute, University Health Network, Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada (H.S.C., J.E.F.); Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden (L.P.M., U.H.); and Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.). krayner@ottawaheart.ca.
Abstract
OBJECTIVE: During inflammation, macrophages secrete vesicles carrying RNA, protein, and lipids as a form of extracellular communication. In the vessel wall, extracellular vesicles (EVs) have been shown to be transferred between vascular cells during atherosclerosis; however, the role of macrophage-derived EVs in atherogenesis is not known. Here, we hypothesize that atherogenic macrophages secrete microRNAs (miRNAs) in EVs to mediate cell-cell communication and promote proinflammatory and proatherogenic phenotypes in recipient cells. APPROACH AND RESULTS: We isolated EVs from mouse and human macrophages treated with an atherogenic stimulus (oxidized low-density lipoprotein) and characterized the EV miRNA expression profile. We confirmed the enrichment of miR-146a, miR-128, miR-185, miR-365, and miR-503 in atherogenic EVs compared with controls and demonstrate that these EVs are taken up and transfer exogenous miRNA to naive recipient macrophages. Bioinformatic pathway analysis suggests that atherogenic EV miRNAs are predicted to target genes involved in cell migration and adhesion pathways, and indeed delivery of EVs to naive macrophages reduced macrophage migration both in vitro and in vivo. Inhibition of miR-146a, the most enriched miRNA in atherogenic EVs, reduced the inhibitory effect of EVs on macrophage migratory capacity. EV-mediated delivery of miR-146a repressed the expression of target genes IGF2BP1 (insulin-like growth factor 2 mRNA-binding protein 1) and HuR (human antigen R or ELAV-like RNA-binding protein 1) in recipient cells, and knockdown of IGF2BP1 and HuR using short interfering RNA greatly reduced macrophage migration, highlighting the importance of these EV-miRNA targets in regulating macrophage motility. CONCLUSIONS: EV-derived miRNAs from atherogenic macrophages, in particular miR-146a, may accelerate the development of atherosclerosis by decreasing cell migration and promoting macrophage entrapment in the vessel wall.
OBJECTIVE: During inflammation, macrophages secrete vesicles carrying RNA, protein, and lipids as a form of extracellular communication. In the vessel wall, extracellular vesicles (EVs) have been shown to be transferred between vascular cells during atherosclerosis; however, the role of macrophage-derived EVs in atherogenesis is not known. Here, we hypothesize that atherogenic macrophages secrete microRNAs (miRNAs) in EVs to mediate cell-cell communication and promote proinflammatory and proatherogenic phenotypes in recipient cells. APPROACH AND RESULTS: We isolated EVs from mouse and human macrophages treated with an atherogenic stimulus (oxidized low-density lipoprotein) and characterized the EV miRNA expression profile. We confirmed the enrichment of miR-146a, miR-128, miR-185, miR-365, and miR-503 in atherogenic EVs compared with controls and demonstrate that these EVs are taken up and transfer exogenous miRNA to naive recipient macrophages. Bioinformatic pathway analysis suggests that atherogenic EV miRNAs are predicted to target genes involved in cell migration and adhesion pathways, and indeed delivery of EVs to naive macrophages reduced macrophage migration both in vitro and in vivo. Inhibition of miR-146a, the most enriched miRNA in atherogenic EVs, reduced the inhibitory effect of EVs on macrophage migratory capacity. EV-mediated delivery of miR-146a repressed the expression of target genes IGF2BP1 (insulin-like growth factor 2 mRNA-binding protein 1) and HuR (humanantigen R or ELAV-like RNA-binding protein 1) in recipient cells, and knockdown of IGF2BP1 and HuR using short interfering RNA greatly reduced macrophage migration, highlighting the importance of these EV-miRNA targets in regulating macrophage motility. CONCLUSIONS: EV-derived miRNAs from atherogenic macrophages, in particular miR-146a, may accelerate the development of atherosclerosis by decreasing cell migration and promoting macrophage entrapment in the vessel wall.
Authors: Janine M van Gils; Bhama Ramkhelawon; Luciana Fernandes; Merran C Stewart; Liang Guo; Tara Seibert; Gustavo B Menezes; Denise C Cara; Camille Chow; T Bernard Kinane; Edward A Fisher; Mercedes Balcells; Jacqueline Alvarez-Leite; Adam Lacy-Hulbert; Kathryn J Moore Journal: Arterioscler Thromb Vasc Biol Date: 2013-02-21 Impact factor: 8.311
Authors: Alma Zernecke; Kiril Bidzhekov; Heidi Noels; Erdenechimeg Shagdarsuren; Lin Gan; Bernd Denecke; Mihail Hristov; Thomas Köppel; Maliheh Nazari Jahantigh; Esther Lutgens; Shusheng Wang; Eric N Olson; Andreas Schober; Christian Weber Journal: Sci Signal Date: 2009-12-08 Impact factor: 8.192
Authors: Fabio Jimenez; Marlon P Quinones; Hernan G Martinez; Carlos A Estrada; Kassandra Clark; Edgar Garavito; Jessica Ibarra; Peter C Melby; Seema S Ahuja Journal: J Immunol Date: 2010-04-19 Impact factor: 5.422
Authors: Henry S Cheng; Rickvinder Besla; Angela Li; Zhiqi Chen; Eric A Shikatani; Maliheh Nazari-Jahantigh; Adel Hammoutène; My-Anh Nguyen; Michele Geoffrion; Lei Cai; Nadiya Khyzha; Tong Li; Sonya A MacParland; Mansoor Husain; Myron I Cybulsky; Chantal M Boulanger; Ryan E Temel; Andreas Schober; Katey J Rayner; Clinton S Robbins; Jason E Fish Journal: Circ Res Date: 2017-06-21 Impact factor: 17.367
Authors: Joseph R Iacona; Nicholas J Monteleone; Alexander D Lemenze; Ashley L Cornett; Carol S Lutz Journal: RNA Biol Date: 2019-08-23 Impact factor: 4.652
Authors: Mariano Carossino; Pouya Dini; Theodore S Kalbfleisch; Alan T Loynachan; Igor F Canisso; Kathleen M Shuck; Peter J Timoney; R Frank Cook; Udeni B R Balasuriya Journal: J Virol Date: 2018-04-13 Impact factor: 5.103
Authors: Bronson A Haynes; Li Fang Yang; Ryan W Huyck; Eric J Lehrer; Joshua M Turner; Nektarios Barabutis; Vanessa L Correll; Allison Mathiesen; William McPheat; O John Semmes; Anca D Dobrian Journal: Arterioscler Thromb Vasc Biol Date: 2019-08-22 Impact factor: 8.311